SAREPTA THERAPEUTICS, INC. Q1 2020 EARNINGS CONFERENCE CALL
FORWARD-LOOKING STATEMENTS

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities and research and development programs including: the expected or potential impact of the COVID-19 pandemic on our business, including the expectation that COVID 19 will have a modest and short term negative impact to revenue, anticipated delays and disruptions in our ongoing and planned clinical trials, and potential payer delays in processing reauthorizations; Sarepta being in a strong position to weather any COVID-related uncertainties, stay focused on executing its plans, drive its strategic plans and emerge from this pandemic on track; the expectation that our supply chain will remain fully intact and that we will be able to continue to manufacture and supply therapy without interruption throughout the pandemic; the expectation that more patients will initiate treatment as COVID-19 restrictions ease and clinics resume normal operations; the potential benefits of our collaboration with Roche; PPMO's potential to have a profound advancement over PMO; our RNA-based candidates' potential to treat COVID-19; the expectation that patient demographics for VYONDYS 53 will be similar to EXONDYS 51; our belief that over time patients will receive access and reimbursement for VYONDYS 53 and start therapy in a timely manner; the potential to launch casimersen in 2021; our belief that the data from LGMD2E will inform the dose selection and accelerate the development pathway for our other sarcoglycan programs and will have some read through to our micro-dystrophin study; our dose escalation and analysis plans for SRP-5051; the potential of our already built PPMO candidates to treat over 50% of the Duchenne population; our plan to bring the PPMO platform to the rarer exon populations, which have the potential to treat another 35% of the addressable population; our PPMO platform's potential viability for new therapeutic areas; expected plans and milestones, including our plans to have a read out of study 102 for SRP-9001 in Q1 2021, to have GMP material for SRP-9001 in July 2020, to commence study 301 in H2 2020, to release expression and safety data from our 3-patient cohort in our high-dose arm for SRP-9003 in Q2 2020, to make a formal dose selection decision in Q3 2020 and to commence the pivotal trial for LGMD2E in 2021, to complete our rolling submission for Casimersen in Q2 2020, to provide a data release on SRP-5051 in H2 2020, and the expectation to dose all patients in the MPS3A gene therapy trial by mid-2020.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the COVID-19 pandemic is expected to reduce our revenue and may negatively impact our ongoing and planned clinical trials, manufacturing and other business operations; the commercial launch for VYONDYS 53 in the U.S. may not be successful for various reasons including the degree to which VYONDYS 53 is accepted by patients and prescribed by physicians, manufacturing limitations, and competitive, reimbursement and regulatory conditions that could negatively impact the launch; we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for casimersen, SRP-5051, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the expected benefits and opportunities related to our agreements with our strategic partners may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreements, challenges and uncertainties inherent in product research and development and manufacturing limitations; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, some of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2019 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.